New Test for HER2+ Breast Cancer to Personalize Therapy

The multiparameter molecular classifier test has a high negative predictive value (NPV), underscoring its accuracy for identifying patients who may not be good candidates for treatment de-escalation.

Related Keywords

Houston ,Texas ,United States ,Baylor College Of Medicine ,Mothaffarf Rimawi ,Rachel Schiff ,Jamunarani Veeraraghavan ,Smith Breast Center ,Breast Cancer Program ,Clinical Cancer Research ,Duncan Cancer Center ,Duncan Comprehensive Cancer Center ,Baylor College ,Clinical Cancer ,Duncan Cancer ,